Erdafitinib | List of Frontiers open access articles

Original Research

Published on 25 Jun 2020

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

in Pharmacology of Anti-Cancer Drugs

Weiguo Feng
Meng Zhang
Zhuo-Xun Wu
Jing-Quan Wang
Xing-Duo Dong
Yuqi Yang
Qiu-Xu Teng
Xuan-Yu Chen
Qingbin Cui
Dong-Hua Yang

Frontiers in Oncology

doi 10.3389/fonc.2020.00955

7,574 views
45 citations

Original Research

Published on 29 Nov 2021

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS

in Drug Metabolism and Transport

Lan-hong Ruan
Ling-ling Fan
Kun Wang
Wan-qi Zhang
Xiao-jun Wang
Xiang-jun Qiu

Frontiers in Pharmacology

doi 10.3389/fphar.2021.749169

4,209 views
11 citations

Original Research

Published on 05 Jun 2025

Erdafitinib diminishes LPS-mediated neuroinflammatory responses through NLRP3 in wild-type mice

in Inflammation Pharmacology

Hyun-ju Lee
Se Ha Kim
Tae-Mi Jung
Yu-Jin Kim
Chan-Hu Gu
Yoo Joo Jeong
Jeong-Heon Song
Hyang-Sook Hoe

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572604

3,902 views
1 citation

Original Research

Published on 24 May 2023

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

in Genitourinary Oncology

Keren Rouvinov
Eran Levanon
Avivit Peer
Michal Sarfaty
David Sarid
Victoria Neiman
Eduard Grikshtas
Eli Rosenbaum
Igal Kushnir
Barak Talmor

Frontiers in Oncology

doi 10.3389/fonc.2023.1151701

4,697 views
6 citations

Systematic Review

Published on 26 Jan 2023

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis

in Genitourinary Oncology

Xinyi Zheng
Hang Wang
Junyue Deng
Minghe Yao
Xiuhe Zou
Fan Zhang
Xuelei Ma

Frontiers in Oncology

doi 10.3389/fonc.2022.907377

8,779 views
24 citations

Mini Review

Published on 22 Aug 2023

Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy

in Cancer Immunity and Immunotherapy

David J. Benjamin
Robert Hsu

Frontiers in Immunology

doi 10.3389/fimmu.2023.1258388

11,202 views
16 citations

Systematic Review

Published on 08 Aug 2025

Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors

in Genitourinary Oncology

Jiyu Huang
Zihan Wang
Fei Zhao
Adilai Aisa
Shengkai Tian
Siyuan Chen
Lianyi Peng
Xiaolu Yang
Jianxin He
Yue Yang

Frontiers in Oncology

doi 10.3389/fonc.2025.1571434

2,502 views

Original Research

Published on 21 Nov 2023

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study

in Pharmacoepidemiology

Tengfei Yuan
Faping Li
Yuchuan Hou
Hui Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1266890

4,517 views
16 citations

Case Report

Published on 24 May 2024

Case report: Slipped capital femoral epiphysis: a rare adverse event associated with FGFR tyrosine kinase inhibitor therapy in a child

in Neuro-Oncology and Neurosurgical Oncology

Meziane Brizini
Tina Drimes
Catherine Bourne
Jessica Streilein
Annie Drapeau
Jens Wrogemann
Lori Anne Archer
Marc Del Bigio
Magimairajan Issai Vanan

Frontiers in Oncology

doi 10.3389/fonc.2024.1399356

2,830 views
3 citations

Original Research

Published on 06 Dec 2024

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess

in Pharmacology of Anti-Cancer Drugs

Yuanbin Huang
Meiqi Xu
Xinmiao Ma
Wei Wang
Chen Shen
Fei Liu
Zhiqi Chen
Jiawen Wang
Qian Guo
Xiancheng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1503154

3,791 views
7 citations

Original Research

Published on 11 May 2021

Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations

in Head and Neck Cancer

Stefan Holzhauser
Nicole Wild
Mark Zupancic
Ramona G. Ursu
Cinzia Bersani
Anders Näsman
Ourania N. Kostopoulou
Tina Dalianis

Frontiers in Oncology

doi 10.3389/fonc.2021.640490

15,175 views
28 citations

Mini Review

Published on 27 Jan 2021

Novel Combination Therapies for the Treatment of Bladder Cancer

in Pharmacology of Anti-Cancer Drugs

Mei Peng
Di Xiao
Yizhi Bu
Jiahui Long
Xue Yang
Shuhe Lv
Xiaoping Yang

Frontiers in Oncology

doi 10.3389/fonc.2020.539527

17,160 views
49 citations

Articles

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS

Erdafitinib diminishes LPS-mediated neuroinflammatory responses through NLRP3 in wild-type mice

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis

Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy

Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study

Case report: Slipped capital femoral epiphysis: a rare adverse event associated with FGFR tyrosine kinase inhibitor therapy in a child

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess

Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations

Novel Combination Therapies for the Treatment of Bladder Cancer